Dublin, Ireland (PRWEB) February 28, 2013
Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential $6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eying for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential opportunity size for Biosimilar players, with regard to:
- European Experience of Biosimilars
- Current market positioning of Herceptin across geography
- Different technologies deployed by biosimilar players
- Competition – Pipeline of Biosimilar and Biobetters targeting Herceptin
- Potential Market Expansion post expiry of Market Exclusivity
- Defense Strategies deployed by Roche
- Ongoing Clinical trials and their impact on Market Opportunity
- Global Regulatory Process and Hurdles
- Risk/Reward profile of developing Herceptin biosimilar
For more information visit http://www.researchandmarkets.com/research/8p8bc7/risk_reward_of
Research and Markets
Laura Wood, Senior Manager.
Email: press(at)researchandmarkets(dot)com
Phone: +35314151241
Sector: Biotechnology
